Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
94% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. GHDX: No Debt )
GHDX' s 10-Year Cash to Debt Range
Min: 4.9   Max: No Debt
Current: No Debt

Equity to Asset 0.81
GHDX's Equity to Asset is ranked higher than
85% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. GHDX: 0.81 )
GHDX' s 10-Year Equity to Asset Range
Min: -3.56   Max: 0.89
Current: 0.81

-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
90% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 115.25 vs. GHDX: No Debt )
GHDX' s 10-Year Interest Coverage Range
Min: 80.08   Max: 9999.99
Current: No Debt

80.08
9999.99
F-Score: 3
Z-Score: 15.40
M-Score: -3.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.52
GHDX's Operating margin (%) is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. GHDX: -4.52 )
GHDX' s 10-Year Operating margin (%) Range
Min: -12348   Max: 4.01
Current: -4.52

-12348
4.01
Net-margin (%) -4.88
GHDX's Net-margin (%) is ranked higher than
63% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. GHDX: -4.88 )
GHDX' s 10-Year Net-margin (%) Range
Min: -12200   Max: 3.81
Current: -4.88

-12200
3.81
ROE (%) -8.80
GHDX's ROE (%) is ranked higher than
62% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. GHDX: -8.80 )
GHDX' s 10-Year ROE (%) Range
Min: -69.14   Max: 6.8
Current: -8.8

-69.14
6.8
ROA (%) -7.21
GHDX's ROA (%) is ranked higher than
63% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. GHDX: -7.21 )
GHDX' s 10-Year ROA (%) Range
Min: -116.45   Max: 5.49
Current: -7.21

-116.45
5.49
ROC (Joel Greenblatt) (%) -42.11
GHDX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. GHDX: -42.11 )
GHDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1194.05   Max: 69.84
Current: -42.11

-1194.05
69.84
Revenue Growth (%) 12.60
GHDX's Revenue Growth (%) is ranked higher than
87% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. GHDX: 12.60 )
GHDX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 136.8
Current: 12.6

0
136.8
» GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

GHDX Guru Trades in Q2 2013

Steven Cohen Sold Out
Chuck Royce 33,000 sh (-17.5%)
Jim Simons 167,000 sh (-38.03%)
» More
Q3 2013

GHDX Guru Trades in Q3 2013

Chuck Royce 33,000 sh (unchged)
Jim Simons 37,800 sh (-77.37%)
» More
Q4 2013

GHDX Guru Trades in Q4 2013

Paul Tudor Jones 15,100 sh (New)
Steven Cohen 14,221 sh (New)
Jim Simons 52,901 sh (+39.95%)
Chuck Royce 33,000 sh (unchged)
» More
Q1 2014

GHDX Guru Trades in Q1 2014

Jim Simons 108,555 sh (+105.2%)
Chuck Royce 33,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GHDX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.96
GHDX's P/B is ranked higher than
64% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.93 vs. GHDX: 5.96 )
GHDX' s 10-Year P/B Range
Min: 3.3   Max: 14.23
Current: 5.96

3.3
14.23
P/S 3.14
GHDX's P/S is ranked higher than
75% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. GHDX: 3.14 )
GHDX' s 10-Year P/S Range
Min: 2.17   Max: 20.45
Current: 3.14

2.17
20.45
PFCF 2670.00
GHDX's PFCF is ranked higher than
77% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 2670.00 )
GHDX' s 10-Year PFCF Range
Min: 33.81   Max: 2909
Current: 2670

33.81
2909
EV-to-EBIT -40.43
GHDX's EV-to-EBIT is ranked lower than
52% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: -40.43 )
GHDX' s 10-Year EV-to-EBIT Range
Min: 78.7   Max: 514.8
Current: -40.43

78.7
514.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.36
GHDX's Price/Net Cash is ranked higher than
87% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 12.36 )
GHDX' s 10-Year Price/Net Cash Range
Min: 3.64   Max: 22.82
Current: 12.36

3.64
22.82
Price/Net Current Asset Value 9.37
GHDX's Price/Net Current Asset Value is ranked higher than
86% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 9.37 )
GHDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.63   Max: 20.16
Current: 9.37

3.63
20.16
Price/Tangible Book 5.96
GHDX's Price/Tangible Book is ranked higher than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.00 vs. GHDX: 5.96 )
GHDX' s 10-Year Price/Tangible Book Range
Min: 3.3   Max: 11.72
Current: 5.96

3.3
11.72
Price/DCF (Projected) 4.23
GHDX's Price/DCF (Projected) is ranked higher than
80% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 4.23 )
GHDX' s 10-Year Price/DCF (Projected) Range
Min: 4.17   Max: 38.47
Current: 4.23

4.17
38.47
Price/Median PS Value 0.71
GHDX's Price/Median PS Value is ranked higher than
93% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.35 vs. GHDX: 0.71 )
GHDX' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.58
Current: 0.71

0.51
3.58
Earnings Yield (Greenblatt) 0.20
GHDX's Earnings Yield (Greenblatt) is ranked lower than
62% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. GHDX: 0.20 )
GHDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 1.3
Current: 0.2

0.2
1.3
Forward Rate of Return (Yacktman) 0.78
GHDX's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.89 vs. GHDX: 0.78 )
GHDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -37.5   Max: 0.3
Current: 0.78

-37.5
0.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:G7H.Germany
Genomic Health, Inc. was incorporated in Delaware in August 2000. The Company engages in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer.
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Show of support for Genomic Health Jul 10 2014
Genomic Grows on Breast Cancer Test, Margin Pressure Continues Jul 03 2014
GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 19 2014
Genomic Health's Oncotype DX Redefines Breast Cancer Therapy Jun 12 2014
Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of... Jun 11 2014
GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 10 2014
Multiple studies presented at 2014 ASCO® annual meeting reinforce unique, practice-changing value... Jun 10 2014
Genomic Health Up on Fresh Cancer Study Data Jun 05 2014
Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict... Jun 03 2014
Multiple Studies Presented at ASCO® Annual Meeting Demonstrate Unique, Practice-Changing Impact of... Jun 01 2014
Genomic Health Posts Fresh Oncotype DX Data May 30 2014
Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out May 29 2014
Genomic Health to Present at Two Upcoming Investor Conferences May 23 2014
Genomic Health: Study Boosts Oncotype DX Again May 21 2014
Genomic Health announces data reinforcing robustness of Oncotype DX May 20 2014
Genomic Health Announces Data Reinforcing Robustness of Oncotype DX® Prostate Cancer Test at 2014... May 20 2014
Genomic Health Presents New Oncotype DX Data May 19 2014
Genomic Health says studies show test predicts prostate cancer aggressiveness May 16 2014
European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's... May 16 2014
GENOMIC HEALTH INC Financials May 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide